---
title: "Opdivo (nivolumab) in metastatic non-small cell lung cancer: Guidelines questions"
description: "Guidelines questions on Opdivo (nivolumab) in metastatic non-small cell lung cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Does NCCN recommend Opdivo plus Yervoy for first-line metastatic NSCLC? Does NCCN recommend Opdivo plus Yervoy and chemotherapy for metastatic NSCLC? Does NCCN support Opdivo Qvantig for previously treated metastatic NSCLC? 3 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/guidelines"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Opdivo (nivolumab) in metastatic non-small cell lung cancer: Guidelines questions

Manufacturer: Bristol-Myers Squibb Company  
Prescribing information: [Opdivo](https://packageinserts.bms.com/pi/pi_opdivo.pdf)

Questions that apply to every indication of Opdivo are on [Opdivo (nivolumab), all indications](https://www.evicenter.com/medical-information/opdivo).

## Guidelines

<a id="opdivo-nccn-with-yervoy"></a>

### Does NCCN recommend Opdivo plus Yervoy for first-line metastatic NSCLC?

Applies to: First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

> “Nivolumab (OPDIVO) + ipilimumab (YERVOY) is recommended as a Category 1, other recommended, first-line therapy option for eligible patients with metastatic NSCLC with PD-L1 1%–49%, or as useful in certain circumstances, first-line therapy option for eligible patients with metastatic NSCLC with PD-L1 ≥50%, and performance status 0–2, including those who are EGFR,* ALK, ROS1, BRAF V600E, NTRK1/2/3, METex14, and RET negative, and with no contraindications to PD-1 or PD-L1 inhibitors<sup>8</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=Nivolumab%20%28OPDIVO%29%20%2B%20ipilimumab%20%28YERVOY%29%20is,contraindications%20to%20PD%2D1%20or%20PD%2DL1)

> “*EGFR exon 19 deletion, exon 21 L858R, EGFR S768I, L861Q, and/or G719X mutation.<sup>8</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=%2AEGFR%20exon%2019%20deletion%2C%20exon%2021%20L858R%2C%20EGFR%20S768I%2C%20L861Q%2C%20and%2For%20G719X)

<a id="opdivo-nccn-with-yervoy-and-chemo"></a>

### Does NCCN recommend Opdivo plus Yervoy and chemotherapy for metastatic NSCLC?

Applies to: First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

> “Nivolumab (OPDIVO) + ipilimumab (YERVOY) + platinum-doublet chemotherapy* is recommended as a Category 1, other recommended, first-line therapy option for eligible patients with metastatic NSCLC regardless of PD-L1 expression and performance status 0–1, who are EGFR,<sup>†</sup> ALK, ROS1, BRAF V600E, NTRK1/2/3, METex14, and RET negative, and with no contraindications to PD-1 or PD-L1 inhibitors<sup>8</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=Nivolumab%20%28OPDIVO%29%20%2B%20ipilimumab%20%28YERVOY%29%20%2B%20platinum%2Ddoublet%20chemotherapy%2A%20is,contraindications%20to%20PD%2D1%20or%20PD%2DL1)

> “*Histology-based chemotherapy; NSQ: pemetrexed + (carboplatin or cisplatin); SQ: paclitaxel + carboplatin.<sup>1</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=%2AHistology%2Dbased%20chemotherapy%3B%20NSQ%3A%20pemetrexed%20%2B%20%28carboplatin%20or%20cisplatin%29%3B%20SQ%3A%20paclitaxel)

<a id="opdivo-nccn-qvantig"></a>

### Does NCCN support Opdivo Qvantig for previously treated metastatic NSCLC?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “National Comprehensive Cancer Network® (NCCN®) supports substituting nivolumab + hyaluronidase-nvhy (OPDIVO Qvantig) for previously treated metastatic NSCLC<sup>d</sup>”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy#:~:text=National%20Comprehensive%20Cancer%20Network%C2%AE%20%28NCCN%C2%AE%29,Qvantig%29%20for%20previously%20treated%20metastatic)

## Related pages
- [Medical information: Opdivo (nivolumab): Metastatic non-small cell lung cancer](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer)
- [Indication](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/access-and-coverage)
